Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.
Level 5 - mechanism / opinion, no new human data
Molecular profiling and bench-level genomic analysis without clinical intervention data (by design analogy).
PubMed 31097695 · doi:10.1038/s41467-019-09937-w
What was done
The authors examined DNA methylation, chromatin marks (specifically repressive H3K9me3), and transcriptional alterations using human papillomavirus (HPV)-related oropharyngeal carcinoma as a model, followed by validation across multiple other tumor types, to characterize spatial chromatin shifts and gene silencing.
What was found
Aberrant enrichment of repressive H3K9me3 at transcription start sites (TSS) was linked to methylation-associated, tumor-specific gene silencing. A hypermethylated subtype was identified with functional convergence on MYC targets and an association with CREBBP/EP300 mutations. The abstract reports no numerical values, effect sizes, or p-values.
Why it matters
It indicates that cancer-associated gene silencing involves coordinated repressive chromatin marks and DNA hypermethylation at transcription start sites rather than exclusively at classic promoter CpG islands, converging with MYC activation and chromatin modifier mutations.
Limits
The abstract provides no sample sizes, demographic details, or quantitative effect sizes. The observational multi-omic associations across tumors do not establish direct mechanistic causality in the reported summary.
Cited by
- supports DNA methylation at CpG sites generally represses gene expression by rendering genomic regions inaccessible, whereas DNA demethylation is associated with active gene transcription.